Thursday, June 30, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

AKT inhibitor miransertib could be a promising new treatment against low-flow vascular malformations

by Medical Finance
in News
Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

A team of researchers led by Dr. Sandra Castillo and Dr. Mariona Graupera, from the Josep Carreras Leukaemia Research Institute and member of the CIBERONC, have found the AKT inhibitor miransertib could be a new molecular treatment effective against low-flow vascular malformations, a long-awaited milestone. Their results, published at the journal EMBO Molecular Medicine, are based on a new in vivo model of blood vessels growth (angiogenesis) that could become the gold standard for this kind of studies in the short term.

Vascular malformations are a heterogeneous group of diseases characterized by an abnormal growth of blood vessels with a major impact on the patients’ quality of life. These alterations happen anywhere in the body and originate mostly during embryonic development. Either as part of a known syndrome or spontaneous, they usually involve mutations leading to the overactivation of PI3K, a key protein in the internal crosstalk of endothelial cells.

Castillo and Graupera discovered in 2016, in collaboration with Dr. Josep Baselga and Dr. Eulàlia Baselga, that vascular malformations were caused by mutations in PI3K. Since then, inhibitors of the PI3K pathway have been the most obvious candidates to treat these diseases, but a poor understanding of the onset and progression of vascular malformations has hindered major advances so far. The reported results, still in the preclinical arena and far from an actual clinical approach, take the first steps to find molecular features to target with specific drugs.

By using a new mouse retina-derived in vivo model, the researchers have been able to mimic the formation of low-flow vascular malformations and determine that, indeed, the PI3K/AKT signaling pathway is the main affected cellular route. According to the research, mutations in the catalytic domain of PI3K seem to trigger a proliferative state in endothelium cells, those lining the inner part of blood vessels, leading to the formation of the characteristic lesions of the disease.

Piotr Kobialka and Helena Sabata, authors of the research, induced the vascular malformations in mutant mice and then treated them with miransertib, an AKT inhibitor used in anticancer therapy. The researchers reported that, in the model, endothelial cells responded to treatment by reducing its proliferation and its capacity to form altered vasculature. These results were further confirmed by using isolated endothelial cells from actual patients, in vitro.

Furthermore, researchers found that active angiogenesis is needed for the malformations to take place, explaining why low-flow alterations are seldomly produced in adulthood, opening the door to preventive strategies in patients already bearing PI3K mutations. In those patients, abnormal blood vessel formation may happen during their life after wound healing or due to hormonal changes.

Overall, the research proposes the first promising candidate for a future molecular therapy on low-flow vascular malformations and offers a fast and robust preclinical model to study angiogenesis in vivo and develop new and more advanced therapies in the short term.

The current research has been the first collaboration with Dr. Eulàlia Baselga, from Sant Joan de Déu Pediatric Hospital, and involved top level scientists from the Javierre Lab, also at the Carreras Institute, the Uppsala University, the Center for Genomic Regulation and the Hospital de Sant Pau.

Source:

Josep Carreras Leukaemia Research Institute

Journal reference:

Piotr Kobialka, Helena Sabata, Odena Vilalta, Leonor Gouveia, Ana Angulo-Urarte, Laia Muixí, Jasmina Zanoncello, Oscar Muñoz-Aznar, Nagore G. Olaciregui, Lucia Fanlo, Anna Esteve-Codina, Cinzia Lavarino, Biola M. Javierre, Veronica Celis, Carlota Rovira, Susana López-Fernández, Eulàlia Baselga, Jaume Mora, Sandra D. Castillo, Mariona Graupera. “The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib”. EMBO Molecular Medicine (2022) e15619. https://doi.org/10.15252/emmm.202115619

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: The Functional Landscape of SARS-CoV-2 3CL Protease. Image Credit: Natalya Rozhkova / Shutterstock.com

SARS-CoV-2 3CLpro also susceptible to mutations

by Medical Finance
June 30, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a profound impact on society and the economy worldwide. Since its...

Hospitalization risk high for IBD patients with incomplete COVID-19 vaccinations

Study uncovers a class of microbial enzymes that drive ulcerative colitis

by Medical Finance
June 29, 2022
0

Ulcerative colitis, a subtype of inflammatory bowel disease, is a chronic ailment of the colon affecting nearly one million individuals...

Nutritional components hold promise for improving the health and well-being of adults

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

by Medical Finance
June 29, 2022
0

The immune system deteriorates with age, making COVID-19 particularly deadly in older people -; but to date, no clinically available...

First patient-derived stem cell model developed for studying oculocutaneous albinism

New computational approach creates spatial maps of single-cell data within tissues

by Medical Finance
June 29, 2022
0

A new computational approach developed by researchers at The University of Texas MD Anderson Cancer Center successfully combines data from...

Study identifies a new potential pathway for developing therapeutics against Epstein-Barr virus

Researchers offer a clear picture of how the 9-1-1 clamp is recruited to sites of DNA damage

by Medical Finance
June 29, 2022
0

DNA is often likened to a blueprint. The particular sequence of As, Cs, Gs, and Ts in DNA provides information...

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

Research reveals enzyme-driven process that activates anti-cancer molecule

by Medical Finance
June 29, 2022
0

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. The anti-cancer molecule...

Next Post
New cryo-EM method may be able to shortcut a big step in modern vaccine development

Study unveils a precise model for the stinging organelle of starlet sea anemone

First patient-derived stem cell model developed for studying oculocutaneous albinism

Bacterium discovery helps to solve the puzzle of what factors limit cell size

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Image Credit: Kateryna Kon/Shutterstock
    ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential
  • Study: SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. Image Credit: FOTOGRIN/Shutterstock
    Meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply